Interim-Response-Adapted Therapy in Advanced Hodgkin’s Lymphoma: Current Status

Ganesan, Prasanth

doi:10.4103/ijmpo.ijmpo_276_19

Cited by 2 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…• Regular review and revision by the WHO have resulted in identifying newer entities with different prognoses and treatments • It has changed from a one-size-fits-all approach to specific treatment for individual entities 33,49 Response adapted therapy • Minimal residual disease-based treatment tailoring (intensification/allogenic transplant) in acute lymphoid leukemia 44 • Interim PET-based response-adapted therapy in Hodgkin's lymphoma 50 Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloblastic leukemia; CLL, chronic lymphoblastic leukemia; PET, positron emission tomography; WHO, World Health Organization.…”

Section: Prognosismentioning

confidence: 99%

What Does an Adult Hemato-Oncology Physician Expect from a Hematopathologist?

Saj,

Ganesan

2023

Indian J Med Paediatr Oncol

Self Cite

View full text Add to dashboard Cite

Recent advances in the field of hemato-oncology have significantly improved outcomes for patients. However, these changes have also increased the complexity of investigations required at the time of diagnosis and during the follow-up of these patients. Close interaction and exchange of information between the pathologist and the clinician is important for sucessful management of patients. This article briefly discusses the advances in the field and the impact of these changes on the management of patients. A clinician's perspective of what is required from a hematopathologist while managing patients in the current era is presented. An attempt is made to classify the requirements as to what is expected in ideal as well as in resource-limited settings.

show abstract